In a report released today, Ritu Baral from TD Cowen maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report), with a price target of $137.00.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Ritu Baral has given her Buy rating due to a combination of factors that highlight both challenges and potential for Sarepta Therapeutics. Despite the missed revenue estimates for Elevidys in the first quarter of 2025, attributed to physician and patient hesitation following a patient death, administrative delays, and a severe flu season, Baral sees the revised revenue guidance as achievable. The company has adjusted its full-year revenue expectations downward, but these figures are still considered attainable, indicating a potential rebound.
Baral’s analysis also considers the company’s strategic financial adjustments, such as increased operating expenses to incorporate upfront payments and potential milestone payments. Although the first quarter showed a net loss, the expectation of a revenue rebound in the second half of 2025, driven by increased physician and patient confidence, supports the Buy rating. The adjusted sales estimates and the company’s proactive measures to address current challenges contribute to a positive long-term outlook for Sarepta Therapeutics.
Baral covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Sarepta Therapeutics, and Amicus. According to TipRanks, Baral has an average return of 4.5% and a 42.89% success rate on recommended stocks.
In another report released today, Piper Sandler also maintained a Buy rating on the stock with a $70.00 price target.